3-Substituted Piperidine BTK Inhibitors Against Ring Opening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BTK inhibitors face issues with metabolization and degradation of the piperidine ring, leading to reduced binding affinity and drug efficacy, necessitating structural modifications to prevent ring opening and enhance stability.
Innovation Solution
Development of BTK inhibitors with a piperidine ring substituted at the 3-position, such as Compounds of Formula (1)-(9), which include specific substitutions like —OH, —OY, —Y2, and -(halo)2, to enhance stability and prevent metabolization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BTK inhibitors with unsubstituted piperidine ring are used, then the drug can be administered, but the piperidine ring undergoes metabolization and ring opening, reducing binding affinity and drug efficacy
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at the 3-position of the piperidine ring while leaving other positions unchanged. This localized modification provides stability and rigidity precisely where needed to prevent metabolization, without altering the overall molecular structure or binding mode. The substituent at the 3-position specifically addresses the ring opening issue while maintaining the inhibitor's ability to bind to the BTK cysteine residue.
Solution Approach 2:
The patent creates composite molecular structures by combining the piperidine ring with various substituent groups (such as aryl, heteroaryl, or alkyl groups) at the 3-position. This composite approach integrates the stabilizing effect of the substituted piperidine core with the pharmacophoric elements needed for BTK binding, resulting in a molecule that兼具 metabolic stability and target affinity.
2Stability of the object's composition
If structural modifications are made to prevent ring opening, then stability and binding affinity are improved, but the molecular structure becomes more complex
Solution Approach 1:
The patent applies parameter changes by systematically varying the substituent at the 3-position of the piperidine ring (different aryl, heteroaryl, or alkyl groups) to optimize the balance between stability and complexity. By controlling the size, electronic properties, and steric demands of the substituent, the patent achieves enhanced metabolic stability while keeping the molecular complexity within acceptable limits for drug development.
3Stability of the object's composition
If the piperidine ring is substituted at the 3-position, then metabolization and ring opening are prevented, but the synthesis process becomes more challenging
Solution Approach 1:
The patent applies preliminary action by introducing the substituent at the 3-position of the piperidine ring during the early stages of molecule design and synthesis. This upfront modification ensures that the stable, metabolically resistant structure is established before subsequent synthetic steps, avoiding the need for complex post-synthesis modifications or protective group strategies that would complicate the manufacturing process.
Data Source
AI summary
Provided herein are BTK inhibitors containing piperidine modified at the 3-position. Further disclosed are methods of making and using said BTK inhibitors.